Non-pharmaceutical factors for poor glycemic control in 13,970 Chinese women with drug-treated type 2 diabetes: A cross-sectional survey in 77 tertiary hospitals in four Chinese cities

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 1161-1167

  Lu, Juming ^a   Weng, Jianping ^b   Gu, Weijun ^a   Guo, Xiaohui ^c   Yang, Wenying ^d   Zou, Dajin ^e   Zhou, Zhiguang ^f   Zhu, Dalong ^g   Ji, Qiuhe ^h   Ji, Linong ⁱ   Yang, Xilin ^j  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d Sino Japan Friendship Hospital   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

^g THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^h FOURTH MILITARY MEDICAL UNIVERSITY   (China)

ⁱ PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^j TIANJIN MEDICAL UNIVERSITY   (China)

more..

Author keywords

HbA1c< inf> goal; Hyperglycemia; Oral antidiabetic drugs

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD GLUCOSE MONITORING; BODY HEIGHT; CHINA; CHINESE; CITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES CONTROL; DISEASE DURATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG USE; EXPLORATORY RESEARCH; FEMALE; GLYCEMIC CONTROL; HEALTH CARE SURVEY; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK REDUCTION; TERTIARY CARE CENTER;

EID: 84937576196     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S66915     Document Type: Article

References (31)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–321.
2. Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010;6(1):19–25.
3. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med. 2001;249(3):225–235.
4. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28(9):2130–2135.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
7. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
8. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.
9. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
10. Heller SR. A summary of the ADVANCE Trial. Diabetes Care. 2009;32(Suppl 2):S357–S361.
11. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–1418.
12. Franzini L, Ardigo D, Cavalot F, et al. Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND. IT Study Group of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis. 2013;23(3):235–241.
13. Ford ES, Schulze MB, Pischon T, Bergmann MM, Joost HG, Boeing H. Metabolic syndrome and risk of incident diabetes: findings from thEuropean Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovasc Diabetol. 2008;7:35.
14. He Y, Zhai F, Ma G, et al. Abdominal obesity and the prevalence of diabetes and intermediate hyperglycaemia in Chinese adults. Public Health Nutr. 2009;12(8):1078–1084.
15. Chen C, Lu FC. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci. 2004;(Suppl 17): 1–36.
16. American Diabetes Association. Standards of medical care in diabetes –2013. Diabetes Care. 2013;36(Suppl 1):S11–S66.
17. Riddle MC, Karl DM. Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care. 2012;35(10):2100–2107.
18. Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55(3): 636–643.
19. Rosenthal ES, Bashan E, Herman WH, Hodish I. ThEffort required to achieve and maintain optimal glycemic control. J Diabetes Complications. 2011;25(5):283–288.
20. Chan JC, Gagliardino JJ, Baik SH, et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care. 2009;32(2):227–233.
21. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–544.
22. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350.
23. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
25. Yang X, Hsu-Hage B, Zhang H, et al. Gestational diabetes mellitus in women of single gravidity in Tianjin City, China. Diabetes Care. 2002; 25(5):847–851.
26. Jang HC, Min HK, Lee HK, Cho NH, Metzger BE. Short stature in Korean women: a contribution to the multifactorial predisposition to gestational diabetes mellitus. Diabetologia. 1998;41(7):778–783.
27. Asao K, Kao WH, Baptiste-Roberts K, Bandeen-Roche K, Erlinger TP, Brancati FL. Short stature and the risk of adiposity, insulin resistance, and type 2 diabetes in middle age: the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. Diabetes Care. 2006;29(7):1632–1637.
28. Smith GD, Greenwood R, Gunnell D, Sweetnam P, Yarnell J, Elwood P. Leg length, insulin resistance, and coronary heart disease risk: the Caerphilly Study. J Epidemiol Community Health. 2001;55(12):867–872.
29. Blonde L, Karter AJ. Current evidence regarding the value of self-monitored blood glucose testing. Am J Med. 2005;118(Suppl 9A): 20S–26S.
30. Chen HS, Wu TE, Jap TS, Lin SH, Hsiao LC, Lin HD. Improvement of glycaemia control in subjects with type 2 diabetes by self-monitoring of blood glucose: comparison of two management programs adjusting bedtime insulin dosage. Diabetes Obes Metab. 2008;10(1):34–40.
31. Martin S, Schneider B, Heinemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia. 2006;49(2):271–278.